dibotermin alfa

This medicine is authorised for use in the European Union.


This is a summary of the European public assessment report (EPAR) for Inductos. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Inductos.

This EPAR was last updated on 18/09/2018

Authorisation details

Product details
Agency product number
Active substance
dibotermin alfa
International non-proprietary name (INN) or common name
dibotermin alfa
Therapeutic area (MeSH)
  • Tibial Fractures
  • Fracture Fixation, Internal
  • Spinal Fusion
Anatomical therapeutic chemical (ATC) code
Publication details
Marketing-authorisation holder
Medtronic BioPharma B.V.
Date of issue of marketing authorisation valid throughout the European Union
Contact address
Earl Bakkenstraat 10
6422 PJ Heerlen
The Netherlands

Product information

17/08/2018 Inductos - EMEA/H/C/000408 - IA/0090


  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Drugs for treatment of bone diseases

Therapeutic indication

Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition.

Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation.

Assessment history

How useful was this page?

Add your rating